PH12022550112A1 - A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes - Google Patents
A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomesInfo
- Publication number
- PH12022550112A1 PH12022550112A1 PH1/2022/550112A PH12022550112A PH12022550112A1 PH 12022550112 A1 PH12022550112 A1 PH 12022550112A1 PH 12022550112 A PH12022550112 A PH 12022550112A PH 12022550112 A1 PH12022550112 A1 PH 12022550112A1
- Authority
- PH
- Philippines
- Prior art keywords
- polymersomes
- population
- eliciting
- populations
- immune response
- Prior art date
Links
- 229920000575 polymersome Polymers 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 4
- 239000002671 adjuvant Substances 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 230000028993 immune response Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19189549 | 2019-08-01 | ||
| EP20171327 | 2020-04-24 | ||
| PCT/EP2020/071809 WO2021019102A2 (en) | 2019-08-01 | 2020-08-03 | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550112A1 true PH12022550112A1 (en) | 2022-12-19 |
Family
ID=72148072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550112A PH12022550112A1 (en) | 2019-08-01 | 2020-08-03 | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220273792A1 (enExample) |
| EP (1) | EP4007597A2 (enExample) |
| JP (1) | JP7676030B2 (enExample) |
| CN (1) | CN114502191B (enExample) |
| AU (1) | AU2020322107A1 (enExample) |
| BR (1) | BR112022001185A2 (enExample) |
| CA (1) | CA3143533A1 (enExample) |
| PH (1) | PH12022550112A1 (enExample) |
| WO (1) | WO2021019102A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104936579B (zh) * | 2012-11-19 | 2020-02-07 | 新加坡科技研究局 | 用于引发对免疫原的免疫响应的方法 |
| US20180128545A1 (en) | 2016-11-08 | 2018-05-10 | Berry Metal Company | Modular furnace cooling wall |
| US12384811B2 (en) | 2019-04-05 | 2025-08-12 | Academia Sinica | Sialidase-resistant saccharide and method of making and using the same |
| KR102657261B1 (ko) * | 2020-04-03 | 2024-04-15 | 조선대학교산학협력단 | Ｃｏｖｉｄ－１９ 진단을 위한 재조합 코로나－１９ 바이러스 스파이크 단백질의 생산 및 이의 용도 |
| WO2021214339A2 (en) * | 2020-04-24 | 2021-10-28 | Acm Biolabs Pte Ltd | Vaccine against human-pathogenic coronaviruses |
| TWI870591B (zh) | 2020-05-08 | 2025-01-21 | 中央研究院 | 嵌合流感疫苗 |
| JP2023550094A (ja) * | 2020-11-12 | 2023-11-30 | ティースキャン セラピューティクス インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２免疫優性ペプチドの構築物及びその使用 |
| JP2024500360A (ja) * | 2020-12-11 | 2024-01-09 | エイシーエム バイオラブズ プライベート リミテッド | 関連づけられた抗原および関連づけられたアジュバントを有する２つのポリマーソーム集団を投与することによる、Ｔｈ１／Ｔｈ２免疫応答の調整方法 |
| CN117597109A (zh) * | 2021-02-02 | 2024-02-23 | Acm 生物实验室私人有限公司 | 聚合物囊泡相关联的佐剂用于刺激免疫应答的单独使用 |
| WO2022171182A1 (zh) * | 2021-02-10 | 2022-08-18 | 斯微(上海)生物科技股份有限公司 | 一种治疗或者预防冠状病毒病突变株的疫苗试剂 |
| WO2022180635A1 (en) * | 2021-02-25 | 2022-09-01 | Migvax Ltd. | Oral compositions and use of same in vaccination |
| US20240181041A1 (en) * | 2021-03-16 | 2024-06-06 | The Wistar Institute | Adenovirus SARS-CoV-2 Vaccine |
| US20220323569A1 (en) * | 2021-03-30 | 2022-10-13 | Qiang Chen | Plant-produced vlps and ric vaccines |
| WO2022212505A1 (en) * | 2021-03-30 | 2022-10-06 | Arizona Board Of Regents On Behalf Of Arizona State University | Optimal production of sars-cov-2 virus-like particles (vlps) produced in mammalian cells |
| BR112023005961A2 (pt) * | 2021-04-12 | 2023-10-24 | Academia Sinica | Molécula de ácido nucleico modificada, vacina combinada, nanopartícula, nanocluster de mrna, método para prevenir ou tratar uma infecção por coronavírus, método para reforço de uma resposta imune adaptativa, peptídeo imunogênico e composição imunogênica |
| BR112023000666A2 (pt) * | 2021-04-12 | 2023-10-24 | Academia Sinica | Imunógeno, composição imunogênica, método para induzir uma resposta imune contra um coronavírus 2 da síndrome respiratória aguda grave e uso da composição imunogênica |
| CN115337404A (zh) * | 2021-05-12 | 2022-11-15 | 中国医学科学院基础医学研究所 | 细胞微颗粒在治疗呼吸道病毒性肺炎上的应用 |
| WO2022251101A2 (en) * | 2021-05-24 | 2022-12-01 | nference, inc. | Compositions and methods related to surge-associated sars-cov-2 mutants |
| WO2023004415A2 (en) * | 2021-07-22 | 2023-01-26 | University Of Miami | Sars-cov-2 vaccine using bacterial spores expressing antigenic fragments |
| CN113633764B (zh) * | 2021-09-02 | 2024-05-14 | 中国食品药品检定研究院 | 一种含佐剂的新冠dna疫苗 |
| IT202100023816A1 (it) * | 2021-09-16 | 2023-03-16 | Takis S R L | Anticorpo contro SARS-CoV-2 e suoi usi in campo medico. |
| TW202334429A (zh) | 2021-10-01 | 2023-09-01 | 中央研究院 | Sars-cov-2棘蛋白特異性抗體及其用途 |
| WO2023060220A1 (en) * | 2021-10-07 | 2023-04-13 | BioVaxys Inc. | Methods of immunization against coronavirus |
| CN114470186B (zh) * | 2022-02-17 | 2023-10-20 | 唐颐控股(深圳)有限公司 | 一种可吸入式纳米新冠疫苗的制备方法 |
| AU2024252371B2 (en) | 2023-04-08 | 2026-02-12 | Rock Biomedical Inc. | Methods and compositions for dendritic cell targeting nano-delivery |
| US12318485B2 (en) | 2023-04-08 | 2025-06-03 | Rock Biomedical, Inc. | Methods and compositions for targeted delivery by polymersomes |
| WO2024238734A2 (en) | 2023-05-17 | 2024-11-21 | Rock Biomedical Inc. | Mgat1 deficient cells and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354934A (en) | 1993-02-04 | 1994-10-11 | Amgen Inc. | Pulmonary administration of erythropoietin |
| JP2002514397A (ja) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | ＣｐＧオリゴヌクレオチドを用いる造血調節の方法 |
| US6835394B1 (en) * | 1999-12-14 | 2004-12-28 | The Trustees Of The University Of Pennsylvania | Polymersomes and related encapsulating membranes |
| US20080181939A1 (en) * | 1999-12-14 | 2008-07-31 | Trustees Of The University Of Pennsylvania | Polymersomes and related encapsulating membranes |
| EP2281033B1 (en) | 2008-04-17 | 2014-10-15 | Vin de Bona Trading Co Pte | Post release modification of viral envelopes |
| US8323696B2 (en) | 2008-08-29 | 2012-12-04 | Ecole Polytechnique Federale De Lausanne | Nanoparticles for immunotherapy |
| CN102460150B (zh) | 2009-04-20 | 2015-05-20 | 新加坡科技研究局 | 囊泡系统及其用途 |
| CN102917690B (zh) * | 2010-03-19 | 2016-08-24 | 麻省理工学院 | 脂质囊泡组合物和使用方法 |
| EP2601262A4 (en) | 2010-08-05 | 2014-01-22 | Agency Science Tech & Res | VESIGN STRUCTURE WITH SEVERAL CHAMBERS AND METHOD FOR THEIR EDUCATION |
| EP4218808A3 (en) | 2012-03-12 | 2023-08-09 | Advanced BioAdjuvants, LLC | Adjuvant and vaccine compositions |
| DK2906717T3 (en) | 2012-10-11 | 2019-04-01 | Vin De Bona Trading Company Pte Ltd | PROCEDURE FOR PAINTING MICROVESICS |
| CN104936579B (zh) | 2012-11-19 | 2020-02-07 | 新加坡科技研究局 | 用于引发对免疫原的免疫响应的方法 |
| EP2898894A1 (en) | 2014-01-27 | 2015-07-29 | LTS LOHMANN Therapie-Systeme AG | Nano-in-micro particles for intradermal delivery |
| WO2016055611A1 (en) * | 2014-10-09 | 2016-04-14 | Universität Basel | Self-assembled nanostructures and methods of use thereof |
| US9636397B2 (en) | 2015-03-24 | 2017-05-02 | VaxLiant, LLC | Adjuvant compositions and related methods |
| WO2019145475A2 (en) * | 2018-01-25 | 2019-08-01 | Acm Biolabs Pte Ltd | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof |
| CN108969771B (zh) * | 2018-08-07 | 2021-06-29 | 中国医学科学院生物医学工程研究所 | 甘露糖修饰的共载抗原和双免疫激动剂磷脂杂化聚合物囊泡及其制备方法与应用 |
-
2020
- 2020-08-03 BR BR112022001185A patent/BR112022001185A2/pt unknown
- 2020-08-03 CN CN202080068673.4A patent/CN114502191B/zh active Active
- 2020-08-03 JP JP2022506401A patent/JP7676030B2/ja active Active
- 2020-08-03 EP EP20758123.2A patent/EP4007597A2/en active Pending
- 2020-08-03 US US17/631,845 patent/US20220273792A1/en active Pending
- 2020-08-03 AU AU2020322107A patent/AU2020322107A1/en active Pending
- 2020-08-03 WO PCT/EP2020/071809 patent/WO2021019102A2/en not_active Ceased
- 2020-08-03 PH PH1/2022/550112A patent/PH12022550112A1/en unknown
- 2020-08-03 CA CA3143533A patent/CA3143533A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022001185A2 (pt) | 2022-03-15 |
| WO2021019102A3 (en) | 2021-03-11 |
| CN114502191A (zh) | 2022-05-13 |
| WO2021019102A2 (en) | 2021-02-04 |
| CA3143533A1 (en) | 2021-02-04 |
| JP2022543038A (ja) | 2022-10-07 |
| US20220273792A1 (en) | 2022-09-01 |
| AU2020322107A1 (en) | 2022-02-03 |
| EP4007597A2 (en) | 2022-06-08 |
| JP7676030B2 (ja) | 2025-05-14 |
| CN114502191B (zh) | 2026-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550112A1 (en) | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes | |
| Akache et al. | Sulfated archaeol glycolipids: Comparison with other immunological adjuvants in mice | |
| Mount et al. | Combination of adjuvants: the future of vaccine design | |
| PH12021552223A1 (en) | Extracellular vesicles for vaccine delivery | |
| TW200722101A (en) | Novel composition | |
| WO2019145475A3 (en) | Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof | |
| MX363529B (es) | Vesículas de membrana externa. | |
| EA201391496A1 (ru) | Иммуногенные композиции и способы применения таких композиций для индукции гуморального и клеточного иммунного ответа | |
| CO2017011245A2 (es) | Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos | |
| MX351074B (es) | Vacunas contra clostridium difficile que comprenden toxinas recombinantes. | |
| WO2022140364A3 (en) | African swine fever (asf) virus vaccines | |
| WO2021204825A3 (en) | INACTIVATED SARS-CoV-2 VIRUS VACCINE | |
| WO2021255690A3 (en) | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof | |
| Hu et al. | Heterologous prime-boost vaccination against tuberculosis with recombinant Sendai virus and DNA vaccines | |
| MX2025006896A (es) | Composiciones inmunogenicas y metodos para provocar una respuesta inmunitaria contra clostridioides (clostridium) difficile | |
| Schmidt et al. | Smart adjuvants | |
| Makinen et al. | CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE) | |
| WO2021247715A3 (en) | Immunogenic francisella antigens and their use in immunization of fish against francisellosis | |
| MX2022012527A (es) | Vacunas, adjuvantes, y metodos para generar una respuesta inmunitaria. | |
| Yu et al. | A new adjuvant MTOM mediates Mycobacterium tuberculosis subunit vaccine to enhance Th1-type T cell immune responses and IL-2+ T cells | |
| PH12022552300A1 (en) | Cpg-adjuvanted sars-cov-2 virus vaccine | |
| PH12022552239A1 (en) | INACTIVATED SARS-CoV-2 VIRUS VACCINE | |
| PH12020500194A1 (en) | Malaria vaccine | |
| CN104027802A (zh) | 一种增强型结核亚单位疫苗 | |
| WO2023014983A3 (en) | Rabbit haemorrhagic disease virus (rhdv) vaccines |